Wells Fargo Maintains Overweight on AptarGroup, Raises Price Target to $132
Wells Fargo analyst Gabe Hajde maintains AptarGroup (NYSE:ATR) with a Overweight and raises the price target from $121 to $132.
Baird Maintains Neutral on AptarGroup, Raises Price Target to $115
Baird analyst Ghansham Panjabi maintains AptarGroup (NYSE:ATR) with a Neutral and raises the price target from $105 to $115.
AptarGroup Q4 Adj. EPS $0.93 Beats $0.79 Estimate, Sales $795.91M Beat $775.57M Estimate
AptarGroup (NYSE:ATR) reported quarterly earnings of $0.93 per share which beat the analyst consensus estimate of $0.79 by 17.72 percent. This is unchanged from the same period last year. The company reported quarterly
Earnings Scheduled For February 16, 2023
Companies Reporting Before The Bell
• RELX (NYSE:RELX) is estimated to report earnings for its Fiscal Year 2022.
• Coca-Cola Europacific (NASDAQ:CCEP) is expected to report earnings for its Fiscal Year 2022.
Aptar Pharma, Part Of AptarGroup Inc Announces The Launch Of APF Futurity, Its First Metal-free, Multidose Nasal Spray Pump
The spray pump is developed to deliver nasal saline and other comparable over-the-counter (OTC) formulations.
Aptar Announces The Realignment Of Two Of Its Business Reporting Segments
AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, consumer product dispensing and active material science solutions and services, today announced that it will realign two of its business reporting segments
Earnings Scheduled For October 27, 2022
Companies Reporting Before The Bell
• Janus Henderson Gr (NYSE:JHG) is expected to report quarterly earnings at $0.48 per share on revenue of $494.27 million.
Aptar And Chiesi Sign Digital Health Contract To Bring Best-In-Class Disease Management Platform For Patients With Asthma And COPD
Aptar Digital Health and Chiesi will offer patients a comprehensive set of services and solutions
Aptar Digital Health, part of Aptar Pharma, a global leader in drug delivery and active material science solutions and
Aptar Pharma Pays Pharmaxis $5M to Acquire Orbital Technology
Clinical stage drug developer Pharmaxis (ASX: PXS) today announced that Aptar Pharma, a global leader in drug delivery systems, services and active material science solutions, has exercised the option to acquire the worldwide rights to Pharmaxis' proprietary inhaler Orbital, a unique device designed to deliver high payload dry powder to the lungs.